Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 169

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Nivolumab Is Effective in Mismatch Repair–Deficient Noncolorectal Cancers: Results From Arm Z1D—A Subprotocol of the NCI-MATCH (EAY131) Study

Open access
Azad, Nilofer S., Gray, Robert J., Overman, Michael J., Schoenfeld, Jonathan D., Mitchell, Edith P., Zwiebel, James A., Sharon, Elad, Streicher, Howard, Li, Shuli, McShane, Lisa M., Rubinstein, Larry, Patton, David R., Williams, P. Mickey, Coffey, Brent, Hamilton, Stanley R., Bahary, Nathan, Suga, J. Marie, Hatoum, Hassan, Abrams, Jeffrey S., Conley, Barbara A., Arteaga, Carlos L., Harris, Lyndsay, O'Dwyer, Peter J., Chen, Alice P., Flaherty, Keith T.·2020·Journal of Clinical Oncology

Abstract

PURPOSE: The National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH) trial, the largest national precision oncology study to date (> 1,100 sites) of patients with relapsed or refractory malignancies, assigned patients to targeted therapy in parallel phase II studies based on tumor molecular alterations. The anti–programmed death receptor 1 inhibitor nivolumab previously showed activity in mismatch repair (MMR)–deficient colon cancer. We hypothesized that nivolumab would have activity in patients with MMR-deficient, noncolorectal tumors. PATIENTS AND METHODS: Eligible patients with relapsed or refractory tumors, good end-organ function, and Eastern Cooperative Oncology Group performance status of ≤ 1 underwent tumor biopsy for centralized screening of molecular alterations. MMR deficiency was defined by complete loss of nuclear expression of MLH1 or MSH2 MMR gene products by immunohistochemistry (IHC). Patients with MMR-deficient colorectal cancer were excluded. Nivolumab, 3 mg/kg every 2 weeks (28-day cycles) and 480 mg every 4 weeks after cycle 4, was administered intravenously. Disease reassessment was performed every 2 cycles. The primary end point was RECIST 1.1 objective response rate (ORR). RESULTS: Two percent of 4,902 screened patients had an MMR-deficient cancer by IHC. Forty-two evaluable patients were enrolled, with a median age of 60 years and a median of 3 prior therapies. The most common histologies were endometrioid endometrial adenocarcinoma (n = 13), prostate adenocarcinoma (n = 5), and uterine carcinosarcoma (n = 4). ORR was 36% (15 of 42 patients). An additional 21% of patients had stable disease. The estimated 6-, 12-, and 18-month progression-free survival rates were 51.3% (90% CI, 38.2% to 64.5%), 46.2% (90% CI, 33.1% to 59.3%), and 31.4% (90% CI, 18.7% to 44.2%), respectively. Median overall survival was 17.3 months. Toxicity was predominantly low grade. CONCLUSION: A variety of refractory cancers (2.0% of those screened) had MMR deficiency as defined in NCI-MATCH. Nivolumab has promising activity in MMR-deficient noncolorectal cancers of a wide variety of histopathologic types.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.19.00818

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 169

Metadata

Authors
Azad, N. S., Gray, R. J., Overman, M. J., Schoenfeld, J. D., Mitchell, E. P., Zwiebel, J. A., Sharon, E., Streicher, H., Li, S., McShane, L. M., Rubinstein, L., Patton, D. R., Williams, P. M., Coffey, B., Hamilton, S. R., Bahary, N., Suga, J. M., Hatoum, H., Abrams, J. S., Conley, B. A., Arteaga, C. L., Harris, L., O'Dwyer, P. J., Chen, A. P., & Flaherty, K. T.
Venue
Journal of Clinical Oncology
Published
2020-01-20
Volume
38
Issue
3
Pages
214-222
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2991389580
Cited by
169
References
7
FWCI
7.44
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Nivolumab Is Effective in Mismatch Repair–Deficient Noncolorectal Cancers: Results From Arm Z1D—A Subprotocol of the NCI-MATCH (EAY131) Study. https://app.cochat.ai/papers/10.1200/jco.19.00818
The paper
Azad, N. S., Gray, R. J., Overman, M. J., Schoenfeld, J. D., Mitchell, E. P., Zwiebel, J. A., Sharon, E., Streicher, H., Li, S., McShane, L. M., Rubinstein, L., Patton, D. R., Williams, P. M., Coffey, B., Hamilton, S. R., Bahary, N., Suga, J. M., Hatoum, H., Abrams, J. S., . . . Flaherty, K. T. (2020). Nivolumab Is Effective in Mismatch Repair–Deficient Noncolorectal Cancers: Results From Arm Z1D—A Subprotocol of the NCI-MATCH (EAY131) Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.19.00818

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.